
The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact was intense: big pharma stocks such as Eli Lilly And Co (NYSE: LLY), Pfizer Inc (NYSE: PFE), and AstraZeneca PLC (NYSE: AZN) fell under pressure initially, pulling pharmaceutical ETFs down.
Also Read: Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs